232
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study

, , , , , , , , & show all
Pages 1173-1184 | Published online: 18 Apr 2022

Figures & data

Table 1 Comparison of Clinical and Laboratory Characteristics at Baseline and the 12th Month Between Lipid-Lowering Group and Control Group

Figure 1 Decrease trends of transaminases and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). Repeated-measures analysis of variance (ANOVA) for the comparison of effects on ALT (A), AST (B), GGT (C), total cholesterol (D), triglyceride (E), and LDL-c (F) between lipid-lowering group and control group. P values were for the ANOVA analysis between the two groups.

Abbreviations: ALT, alanine aminotransferease; AST, aspartate aminotransferase; GGT, gamma glutamyltranspeptidase; LDL-c, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
Figure 1 Decrease trends of transaminases and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). Repeated-measures analysis of variance (ANOVA) for the comparison of effects on ALT (A), AST (B), GGT (C), total cholesterol (D), triglyceride (E), and LDL-c (F) between lipid-lowering group and control group. P values were for the ANOVA analysis between the two groups.

Figure 2 Correlation analysis between changes in transaminase and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). ***P < 0.001, **P < 0.01. *P < 0.05.

Abbreviations: Δ, changes; ALT, alanine aminotransferease; AST, aspartate aminotransferase; GGT, gamma glutamyltranspeptidase; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ApoE, apolipoprotein E.
Figure 2 Correlation analysis between changes in transaminase and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). ***P < 0.001, **P < 0.01. *P < 0.05.

Figure 3 The impact of declining blood lipid levels on transaminase and GGT normalization. Comparison of transaminase and GGT normalization rate between the lipid-lowering group (n = 325) and control group (n = 216) (A), statin group (n = 216) and fibrate group (n = 91) (B and C), MAFLD with T2DM group (n = 67) and without T2DM group (n = 258), the male group (n = 241) and female group (n = 84) (C), and groups of 3 different reduction ranges in blood lipids (G). Comparison of LDL-c (D) and non-HDL-c (E) treated to target rate between the lipid-lowering group and the control group. Comparison of reduction ranges in blood lipids between the transaminase and GGT normalization group (n = 169) and nonnormalized group (n = 156) (F). ***P < 0.001, *P < 0.05.

Abbreviations: ALT, alanine aminotransferease; AST, aspartate aminotransferase; GGT, gamma glutamyltranspeptidase; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; CVD, cardiovascular disease; T2DM, type 2 diabetes.
Figure 3 The impact of declining blood lipid levels on transaminase and GGT normalization. Comparison of transaminase and GGT normalization rate between the lipid-lowering group (n = 325) and control group (n = 216) (A), statin group (n = 216) and fibrate group (n = 91) (B and C), MAFLD with T2DM group (n = 67) and without T2DM group (n = 258), the male group (n = 241) and female group (n = 84) (C), and groups of 3 different reduction ranges in blood lipids (G). Comparison of LDL-c (D) and non-HDL-c (E) treated to target rate between the lipid-lowering group and the control group. Comparison of reduction ranges in blood lipids between the transaminase and GGT normalization group (n = 169) and nonnormalized group (n = 156) (F). ***P < 0.001, *P < 0.05.

Table 2 Univariate and Multivariate Analyses of Factors Associated with Transaminase and GGT Normalization by Lipid-Lowering Agents